Neueste

  • Neue Fortschritte bei der Untersuchung des Mechanismus von Lianhua Qingwen-Kapseln zur Behandlung von COVID-19

    ​Kürzlich haben Prof. Caisheng Wu und Prof. Yifeng Chai von der School of Pharmacy, Xiamen University neue Fortschritte bei der Untersuchung der pharmakologisch aktiven Inhaltsstoffe und des Mechanismus von Lianhua Qingwen Kapseln bei der Prävention und Behandlung von COVID-19 gemacht. Das Ergebnis der Studie, "Screening of the Anti-COVID-19 Pharmacological Active Ingredients of Traditional Chines
  • Yutong совместно с компанией Mowasalat обслуживает Клубный чемпионат мира по футболу 2020 в Катаре

    4 февраля 2021 года в Катаре официально начался 17-й Клубный чемпионат мира по футболу ФИФА, в рамках которого в городе Доха собрались ведущие футбольные клубы из 5 континентов. Среди них такие звездные команды, как победитель Лиги чемпионов УЕФА — германский футбольный клуб «Бавария» и местный клуб Аль-Духайль. В чемпионате также приняли участие такие команды, как Палмейрас из Бразилии, Ульсан Хё
  • Equipped with UNISOC T618, ZTE Axon 20 4G with Under-Screen Camera Has Been Launched Overseas

    Shanghai, China, December X, 2020 - The 4G version of the flagship ZTE cellphone, the Axon 20 4G, with an under-screen camera, powered by a UNISOC T618 chipset, which is an 8-core CPU, is announced to be launched on the overseas markets such as Germany and Mexico.
  • The world’s first 4G camera-under-screen cellphone represents the coming era of the real full-screen cellphone

    The under-screen camera and the extremely narrow border can provide its users with bigger game graphics, and the length-to-width ratio is close to that of the movie screen-all bringing shocking visual effects.
  • BYD Wins the Largest Pure-Electric Bus Order outside of China

    Bogotá, Colombia - BYD is proud to announce that it has exclusively won cumulative orders to supply 1,002-unit pure-electric buses to the capital of Colombia, Bogotá. This tender was open to all bus technologies, yet BYD won the trust and cooperation of its partners in the fiercely competitive bidding process thanks to its cutting-edge technologies, products and services. This is the largest order
  • Dab the 5G Era with the Perfume of Books and Fragrance of Ink — allow full rein to a better life with Hisense A7

    On Dec 22nd, Hisense’s new reading flagship cellphone A7 series was officially launched. This series is the continuation of the characteristics of Hisense A series' most typical ink screen design, namely e-ink screen, a kind of screen that uses electronic ink, which is also known as e-paper displays. This is the world's first 5G cellphone equipped with an ink screen, marking the official arrival o
  • BYD Delivers Largest Pure Electric Bus Fleet in Colombia

    Bogota, Colombia - On December 17, BYD announced the delivery of 470 pure electric buses to Bogota, the capital of Colombia. This is the country’s largest pure electric bus fleet, and also the largest bus fleet BYD has delivered in the Americas, which will effectively promote the already fast-growing electrified public transport systems in Colombia, Latin America and the entire Americas.
  • UNISOC and CTTL Helped Fibocom to Obtain the World's First Cat.1bis Module GCF Certification

    On December 21, 2020, UNISOC, China Telecommunication Technology Labs (CTTL) and Fibocom jointly announced that Fibocom L610-EU module was officially awarded the world's first 3GPP UE category 1bis module (Cat.1bis for short) GCF/CE/NCC certification, which marked that the Fibocom Cat.1bis module equipped with the UNISOC 8910DM chip has the overseas supply capacity officially.
  • New Sapphire Timepiece by AET REMOULD - Sapphire Daytona

    On Christmas Eve, AET REMOULD specially launched the sapphire Daytona Xmas, which uses AET REMOULD's iconic sapphire crystal material and creates a brand new sapphire crystal Daytona.
  • Industry's First 5G Terminal Slicing Solution Demonstrated

    SHANGHAI, Dec 4, 2020 - UNISOC, with China Mobile, ZTE and other industry chain partners, jointly completed an application demonstration of the world's first 5G terminal slicing target solution, which indicates that 5G terminal has been equipped with the slicing capability and can provide personalized and customized services for 5G users. The demonstration took place at the 8th China Mobile Globa

Link

Celartics Biopharma's dendritic cell-based vaccine against COVID-19 infection found to efficiently produce viral antigen-specific T lymphocytes

05-22    

Results from ongoing study suggest the major role of Celartics' Cov-DCVax in preventing viral infection of COVID-19 and in controlling progression of the virus-associated diseasesBeijing, May 22, 2020, Celartics Biopharma announced today the filing of a patent application covering a novel dendritic cell (DC)-based vaccine, Cov-DCVax, to fight viral infection of COVID-19. The results, led by Celartics research team, demonstrate that using the proprietary engineered DC technology by targeting nucleoprotein (NP) of COVID-19, NP-specific cytotoxic CD8+ T cells from naive T lymphocytes can be efficiently induced and massively expanded in culture. The antigen-loaded DCs and viral antigen-specific T cells have great potentials in preventing viral infection and in controlling progression of virus-associated diseases, respectively.

Dendritic cells are the most potent professional antigen-presenting cells that can engulf and process viral or tumor antigens. Once DCs are loaded with viral antigen and become activated, they acquire the ability to educate naïve T lymphocytes, promoting these T cells to differentiate into antigen-specific cytotoxic T cells that can fight virus. Primary blood DCs constitute 1% of immune cells in peripheral blood and are not able to grow in culture. Manufacturing clinical grade DC with the conventional DC method, therefore, needs quite large amount of blood and is very costly, limiting DC’s application as a preventive vaccine against viral infection. To overcome various technical hurdles associated with the conventional DC method, Celartics Biopharma has developed an innovative engineered DC technology, which enables primary blood DCs from a few milliliters of peripheral blood to grow in culture, generating large amounts of highly activated DCs suitable for multiple clinical applications. These engineered DCs exhibit vastly improved antigen-loading capability and efficient lymphoid tissue homing ability due to high expression of the chemokine receptor, CCR7. In addition, the manufacturing cost for generating engineered DCs is significantly reduced. “The engineered DCs are safe to use, as demonstrated in animal studies and pilot clinical trial in cancer immunotherapy”, said Yang Yu, CEO of Celartics Biopharma

Current vaccine strategies for COVID-19 include mRNA vaccine, DNA vaccine, adenovirus vector-based vaccine and inactivated virus vaccine, with the goal of generating neutralizing antibody that reacts to Spike, the viral surface protein of COVID-19. The neutralizing antibody blocks entry of virus to host cells through ACE2 receptor. Accumulating evidences have suggested that developing permanent immunity remains challenging, exclusively by targeting heavily glycosylated Spike protein or rapidly mutating viral surface proteins such as influenza HA. Differing from these vaccine strategies, the engineered DCs are designed to empower T cells to fight virus. DC-educated T cells recognize viral antigenic peptides complexed with HLA molecules on the surface of virus-harboring host cells and launch subsequent attack to eliminate virus. Furthermore, a given viral protein in host cells is processed into multiple antigenic peptides that are bound to distinct HLA molecules, this provides many targets for antigen-specific T cells to attack. Unlike Spike protein, the NP protein of COVID-19 is less likely to mutate and also share 91% amino acid sequence homology with the counterpart of SARS virus. “The Cov-DCVax is designed to develop long-lasting protective immunity in human to fight both COVID-19 and SARS viruses”, said Yang Yu.

In last February, Celartics Biopharma announced the development of Human Dendritic Cell and Data Repository (HDCR), in order to meet urgent demands in fighting deadly virus outbreak and cancer. HDCR prepares human blood dendritic cells from healthy individuals in GMP facility, coupled with data analysis covering immunophenotyping and HLA typing. These engineered DCs are stored in liquid nitrogen and are readily available when needed, in supporting cell-based vaccination or immunotherapy. HDCR also serves as the platform technology provider to research institutions and pharmaceutical industries. The ultimate goal of HDCR is to bring in a feasibility of dendritic cells as a new form of preventive vaccines for rapidly evolving viruses. The Cov-DCVax vaccine is intended for generating long-lasting protective immunity in high risk individuals, while the viral antigen-specific T cells provide immediate therapeutic protection in controlling the progression of COVID-19-associated disease. "The current research progress and patent application enhance the spectrum of possible collaborators and partners. We are delighted that our scientific team has made solid progress in developing such unique Cov-DCVax vaccine, which may potentially yield benefits useful to high risk population, considering current global impact and severity of COVID-19 pandemic", said Yang Yu, CEO of Celartics Biopharma.


About Celartics Biopharma, Inc. Celartics Biopharma is a biotechnology company, located at Dongsheng International Science Park, Beijing. The company focuses on developing innovative cell-based immunotherapies for human cancer and viral diseases. The Company seeks rapidly advancing these technologies through pre-clinical and Phase I and II clinical trials, centering on DC therapeutic vaccine and adoptive T cell transfer therapies for treating solid cancer and leukemia. The company also seeks potential collaborators and partners for joint development through the proprietary technology platforms.

Ph.D., Chief Technology Officer, Celartics Biopharma, Inc.

Company :Celartics Biopharma Inc., Ltd.  

Contact: Huan Zhang,

Phone:010-6295 5880

Email: lily@celartics.com

Web:http://www.celartics.com/


Haftungsausschluss: Dieser Artikel wurde aus anderen Medien reproduziert. Der Zweck des Nachdrucks besteht darin, mehr Informationen zu vermitteln. Dies bedeutet nicht, dass diese Website ihren Ansichten zustimmt und für ihre Authentizität verantwortlich ist und keine rechtliche Verantwortung trägt. Alle Ressourcen auf dieser Website werden im Internet gesammelt. Der Zweck des Teilens dient nur dem Lernen und Nachschlagen aller. Wenn eine Verletzung des Urheberrechts oder des geistigen Eigentums vorliegt, hinterlassen Sie uns bitte eine Nachricht.
Zurück nach oben
© Urheberrechte 2009-2020 TOM Nachrichtenportal      Kontaktieren Sie Uns   SiteMap